Guilin Sanjin Pharmaceutical Co Ltd - Asset Resilience Ratio
Guilin Sanjin Pharmaceutical Co Ltd (002275) has an Asset Resilience Ratio of 14.80% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Guilin Sanjin Pharmaceutical Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Guilin Sanjin Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Guilin Sanjin Pharmaceutical Co Ltd (002275) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Guilin Sanjin Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Guilin Sanjin Pharmaceutical Co Ltd market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥636.30 Million | 14.8% |
| Total Liquid Assets | CN¥636.30 Million | 14.80% |
Asset Resilience Insights
- Moderate Liquidity: Guilin Sanjin Pharmaceutical Co Ltd has 14.80% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Guilin Sanjin Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Guilin Sanjin Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Guilin Sanjin Pharmaceutical Co Ltd (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Guilin Sanjin Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 14.79% | CN¥626.15 Million ≈ $91.62 Million |
CN¥4.23 Billion ≈ $619.31 Million |
+7.05pp |
| 2023-12-31 | 7.74% | CN¥304.69 Million ≈ $44.59 Million |
CN¥3.94 Billion ≈ $575.97 Million |
+3.67pp |
| 2022-12-31 | 4.07% | CN¥161.24 Million ≈ $23.59 Million |
CN¥3.96 Billion ≈ $580.19 Million |
-1.35pp |
| 2021-12-31 | 5.41% | CN¥221.77 Million ≈ $32.45 Million |
CN¥4.10 Billion ≈ $599.35 Million |
-3.74pp |
| 2020-12-31 | 9.15% | CN¥355.34 Million ≈ $52.00 Million |
CN¥3.88 Billion ≈ $568.10 Million |
+7.18pp |
| 2019-12-31 | 1.98% | CN¥67.50 Million ≈ $9.88 Million |
CN¥3.42 Billion ≈ $499.81 Million |
+1.98pp |
| 2018-12-31 | 0.00% | CN¥1.27K ≈ $186.02 |
CN¥3.41 Billion ≈ $498.42 Million |
-11.29pp |
| 2017-12-31 | 11.29% | CN¥364.60 Million ≈ $53.35 Million |
CN¥3.23 Billion ≈ $472.59 Million |
+3.95pp |
| 2016-12-31 | 7.34% | CN¥210.66 Million ≈ $30.83 Million |
CN¥2.87 Billion ≈ $419.95 Million |
+3.51pp |
| 2015-12-31 | 3.83% | CN¥105.60 Million ≈ $15.45 Million |
CN¥2.76 Billion ≈ $403.83 Million |
-5.15pp |
| 2014-12-31 | 8.98% | CN¥250.00 Million ≈ $36.58 Million |
CN¥2.78 Billion ≈ $407.33 Million |
+8.80pp |
| 2010-12-31 | 0.18% | CN¥3.60 Million ≈ $527.15K |
CN¥1.98 Billion ≈ $289.92 Million |
-- |
About Guilin Sanjin Pharmaceutical Co Ltd
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China and internationally. The company offers three gold particles, Guilin watermelon frost, watermelon frost lozenges, throat clearing spray, Naomaitai capsules, vertigo tablets, Xuanyunning granules, Gejie dingchuan capsule, compound panax notoginseng stomachache … Read more